Quantcast

Latest Neuronetics Stories

2014-09-18 04:21:09

HELSINKI, Finland, September 18, 2014 /PRNewswire/ -- New device to be showcased at two international congresses Nexstim (the "Company"), a medical technology company focused on Navigated Brain Stimulation (NBS), announces the launch of a new NBS system, NBS 5, for noninvasive presurgical mapping in clinical neurosurgery. The new device will be showcased at two international neurosurgery congresses during the month of October 2014, one in Europe and the...

2014-09-16 12:31:54

Largest clinical study evaluating durability of treatment with the NeuroStar shows depression patients maintained remission through 52 weeks MALVERN, Pa., Sept. 16, 2014 /PRNewswire/ -- Neuronetics, Inc., today announced that results of a study designed to assess the long-term effectiveness of NeuroStar TMS Therapy in adult patients with Major Depressive Disorder (MDD) who have failed to benefit from prior treatment with antidepressant medications, were published online in The...

2014-09-12 23:02:19

The North America External Neurostimulation/Neuromodulation Devices Market report defines and segments the concerned market in North America with analysis and forecast of revenue. http://www.micromarketmonitor.com/market/north-america-external-neurostimulation-2396937734.html (PRWEB) September 12, 2014 The North America External Neurostimulation/Neuromodulation Devices Market report defines and segments the concerned market in North America with analysis and forecast of revenue. The...

2014-05-06 16:32:06

Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK, May 6, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice...

2014-05-06 14:42:47

Pilot study reveals a majority of medication-free patients treated with NeuroStar TMS experienced remission after 6 weeks with durable effects through 3 months Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy® for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced...

2014-05-05 16:26:47

Pilot Study Reveals a Majority of Medication-Free Patients Treated with NeuroStar TMS Experienced Remission After Six Weeks with Durable Effects Through Three Months NEW YORK, May 5, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(®) for Major Depressive Disorder (MDD)....

2014-01-27 08:28:26

510(k) filing follows recent FDA clearance of CerenaTMS(TM) SUNNYVALE, Calif. and BALTIMORE, Jan. 27, 2014 /PRNewswire/ -- eNeura Inc., a privately held medical technology company, announced today that it filed a 510(k) with the U.S. Food and Drug Administration (FDA) for the SpringTMS(®) transcranial magnetic stimulation (TMS) device. SpringTMS is a second-generation medical device based on eNeura's ground-breaking CerenaTMS(TM), which recently received FDA clearance for the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related